Valentín Ortiz-Maldonado, MD, Hospital Clínic de Barcelona, Barcelona, Spain, shares that the CD19 CAR-T cell product, ARI-0001, is currently under review for approval by the Spanish Drug Agency (AEMPS) under the Hospital Exemption Rule. In addition to this, a Phase II multicenter clinical trial is starting in adult acute lymphoblastic leukemia (ALL) with ARI-0001 cell therapy but with a higher dose to improve the duration of response. This interview took place during the 3rd European CAR T-cell Meeting.
Research grants: Fundación Española de Hematología y Hemoterapia Travel grants: Kite, Celgene, Novartis, Roche, Takeda & Janssen Consultant or advisory fees: Kite, Celgene-BMS & Novartis. Honoraria: Kite